Fairvalue-Calculator Fairvalue-Calculator
EN DE

Energenesis Biomedical CO.,LTD. (6657) Fair Value & Analysis

Healthcare · TW · Market cap 3.0B TWD

Price35.35 TWD
Fair Value45.88 TWD
Upside+29.8%
Quality95/100
Evidence: Low Range 34.41 TWD – 57.35 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Energenesis Biomedical CO.,LTD. (6657) currently trades at 35.35 TWD, while our model-based Fair Value estimate is 45.88 TWD — implying the stock looks roughly 29.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control. The company also offers scientific products, including western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions. Energenesis Biomedical CO.,LTD. was …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Energenesis Biomedical CO.,LTD. (6657) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 45.88 TWD versus a price of 35.35 TWD — about +30% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 6657?
Our 21-model fair value for Energenesis Biomedical CO.,LTD. is 45.88 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 35.35 TWD.
What is the quality score of 6657?
Energenesis Biomedical CO.,LTD. has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.